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Abstract
Clinical studies have demonstrated a correlation between elevated levels of FIX and the risk of coronary heart disease, while
reduced plasma FIX causes hemophilia B. FIXa interacts with FVIIIa in the presence of Ca2+ and phosphatidylserine (PS)-
containing membranes to form a factor X-activating complex (Xase) that is key to propagation of the initiated blood
coagulation process in human. We test the hypothesis that PS in these membranes up-regulates the catalytic activity of this
essential enzyme. We used a soluble form of phosphatidylserine, 1, 2-dicaproyl-sn-glycero-3-phospho-L-serine (C6PS), as a
tool to do so. C6PS and PS in membranes are reported to regulate the homologous FXa nearly identically. FIXa binds a
molecule of C6PS at each of with two sites with such different affinities (,100-fold) that these appear to be independent. A
high affinity C6PS binding site (Kd,1.4 mM) regulates structure, whereas a low-affinity binding site (Kd,140 mM) regulates
activity. Equilibrium dialysis experiments were analyzed globally with four other data sets (proteolytic and amidolytic
activities, intrinsic fluorescence, ellipticity) to unequivocally demonstrate stoichiometries of one for both sites. Michaelis-
Menten parameters for FIXa proteolytic activity were the same in the presence of C6PS or PS/PC membranes. We conclude
that the PS molecule and not a membrane surface is the key regulator of both factors Xa and IXa. Despite some minor
differences in the details of regulation of factors Xa and IXa, the similarities we found suggest that lipid regulation of these
two proteases may be similar, a hypothesis that we continue to test.
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Introduction
Factor X (FX) activation during blood coagulation is carried out
by two alternative enzyme complexes: the extrinsic tenase (Xase)
complex formed by Factor VIIa (FVIIa) and tissue factor (TF) and
the intrinsic tenase complex composed of Factor IXa (FIXa) and
Factor VIIIa (FVIIIa) [1]. There is general consensus that
physiological coagulation is initiated by extrinsic Xase, while its
propagation occurs via intrinsic Xase [1,2]. FIXa is an Mr 44000,
two-chain, vitamin K-dependent serine protease that hydrolyzes
the Arg194-Ile195 peptide bond in the FX molecule to form
activated FX (FXa) [3]. Although this reaction can proceed slowly
in solution, it is significantly accelerated in the presence of
negatively charged phospholipid surfaces [4]. In vivo, these surfaces
are mainly provided by activated platelets or plasma lipoproteins
(in the case of atherosclerotic lesions) [5]. For in vitro studies of FX
activation by intrinsic Xase, synthetic phospholipid vesicles
[usually composed of phosphatidylserine (PS) and phosphatidyl-
choline (PC) in a 25:75 molar ratio] are often used to substitute for
physiological surfaces.
Factor X activation by the intrinsic Xase complex is the rate-
limiting step for thrombin generation during tissue factor-
dependent coagulation [6,7]. Animal models suggest that targeting
of the intrinsic Xase complex may improve the risk/benefit ratio of
antithrombotic therapy. It is well known that micro-particles (MPs,
small membrane-bound vesicles that derive from activated
platelets or damaged endothelial/epithelial cell membranes)
circulate in the peripheral blood and play active roles in
thrombosis, inflammation, and vascular reactivity [8]. In several
disease states characterized by inflammation and vascular
dysfunction, MP subpopulations are elevated, correlate with
clinical events, and may have important roles in pathogenesis.
One of the mechanisms by which platelet-derived MPs elicit
procoagulant activity is by exposure of PS on their surface. It is
likely that PS exposure on MPs also accounts for their role in the
immune response [9] These observations make it imperative to
understand the mechanisms by which PS regulates factors IXa.
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This report aims to increase our understanding of this PS
regulatory mechanism.
PS is a key regulator of the prothrombinase complex [10–13], as
it binds to FXa and FVa, inducing conformational changes in each
that regulate both the activity of FXa and the assembly of the
prothrombinase complex [10–14]. FIXa shows both structural and
sequence homology to FXa [15], making it reasonable to
hypothesize that PS also regulates FIXa. To test this, we employed
dicaproyl-phosphatidylserine (C6PS), which is soluble below its
well-established critical micelle concentration and whose binding
to FXa has been well characterized [12,14,16]. We used intrinsic
fluorescence and circular dichroism (CD) to reveal different
aspects of FIXa structure and found that a Ca2+-dependent tight
binding site is responsible for C6PS-induced conformational
changes. We also tested the ability of C6PS to alter FIXa activity
and found that it caused a ,45 fold increase in proteolytic activity
and 50% decrease in amidolytic activity when bound in a Ca2+-
dependent fashion to weak regulatory sites that are apparently
independent of the tight sites. FIXa with C6PS bound to this weak
regulatory site showed proteolytic activity with Michaelis Menten
constants similar to those obtained with FIXa bound to PS-
containing membranes. We tested several soluble lipids (C6PG,
C6PE, C6PC, C6(D)PS, and C6PA) to assess lipid-specificity and
found that only C6PS bound to FIXa with high affinity and only
C6PS and C6PE elicited changes in activity, although acidic lipids
(C6PG, C6(D)PS, and C6PA) bound with weak affinity to elicit
changes in intrinsic fluorescence. Finally, we confirmed the
existence of only two sites using equilibrium dialysis and analyzed
data from all five types of binding experiments to obtain the
binding constants and stoichiometries of both types of sites. The
results support our hypothesis that PS regulates FIXa similar to
how it regulates FXa, although additional work is required to
reveal the details of this regulation.
Materials and Methods
Materials
1,2-dicaproyl-sn-glycero-3-phospho-L-serine (C6PS) and all
other lipids were purchased from Avanti Polar Lipids Incorporated
(Alabaster, AL). Lipid stock solutions in buffer were prepared by
measuring aliquots of appropriate lipid stocks in chloroform,
evaporating the chloroform under a stream of nitrogen, re-
solubilizing the lipid in cyclohexane, and then lyophilizing frozen
solutions overnight. The resulting dry powder was dispersed in
buffer (20 mM Tris, 150 mM NaCl, pH-7.5) and vortexed
thoroughly [16].
Human FIXa and FX were purchased from Haemotologic
Technologies Incorporated (Essex Junction, VT). The activities of
FIXa and FXa were determined using the synthetic chromogenic
substrates Pefachrome FIXa3960 (Pefa-3960) and Pefachrome
FXa (Pefa-5523) both of which were purchased from Centerchem
Incorporated (Norwalk, CT).
Methods
Human FIXa Amidolytic Activity Assay. The amidolytic
activity of human factor FIXa in the presence of various
concentrations of C6PS was determined using a synthetic
substrate, Pefa-3960. Amidolytic activity was measured in buffer
(20 mM Tris, 150 mM NaCl, 0.6% PEG, pH 7.4, and either
5 mM CaCl2 or 0 mM CaCl2 with 1 mM EDTA) containing
human FIXa (200 nM), chromogenic substrate (500 mM), and
varying concentrations of C6PS (0–700 mM). The time course of
absorbance yielded the amidolytic activity of FIXa. A small
volume (89 mL) of appropriate calcium buffer was first incubated
in a 96 well microplate at 37uC. Human FIXa was next allowed to
bind C6PS by adding both to the buffer in the well and
equilibrated for 5 minutes at 37uC. Finally, 7 mL of 10 mM
Pefa-3960 was added to each well to bring the total volume of each
solution to 140 mL. The absorbance at 405 nm was recorded
every twenty seconds for 30 minutes using a vertically photometric
VersaMax tunable microplate reader (Molecular Devices) to
obtain the initial rate of Pefa-3960 hydrolysis. Rates of synthetic
substrate hydrolysis were reported as a percent of the rate
observed in the absence of phospholipid.
Proteolytic Activity Assay. The calcium- and phosphatidyl-
serine-dependence of the proteolytic activity of FIXa was followed
by measuring the generation of factor Xa amidolytic activity
against the synthetic substrate Pefa-5523 at varying concentrations
of CaCl2 and C6PS. Just as Pefa-3960 is used for FIXa, Pefa-5523
is used for the active site of FXa. Proteolytic activity mixtures
contained buffer (20 mM Tris, 150 mM NaCl, 0.6% PEG,
pH 7.4, 1 mM EDTA with 0, 1, 1.5, 2, 2.5, 3, 4, 5, or 6 mM
CaCl2), human FIXa (5 nM), human FX (300 nM), Pefa-5523
chromogenic substrate (1 mM), and varying concentrations of
C6PS (0–700 mM). A small volume of appropriate calcium buffer
was first equilibrated in a 96 well microplate at 37uC. Human
FIXa was next allowed to bind the appropriate amount of C6PS,
which was added to the well and equilibrated with FIXa at 37uC
for 5 minutes. Finally, a premixed solution of FX and chromo-
genic substrate pre-equilibrated for 2 minutes at 37uC was added
to each well to bring the total volume of each well to 140 mL. After
30 seconds of mixing, the absorbance at 405 nm was recorded
every twenty seconds for one hour using a VersaMax tunable
micro plate reader (Molecular Devices). The data were analyzed as
described elsewhere [17,18] to obtain the initial rate of FX
activation by FIXa.
Circular Dichroism Spectroscopy of FIXa. Circular Di-
chroism spectra of FIXa at 25.9uC were obtained on an Applied
Photophysics (Leatherhead Surrey, Great Britain) Pi-star 180
spectrophotometer using a 1 cm path length cuvette and a 1 nm
bandwidth. The spectra were recorded from 195 to 260 nm at
0.2 nm intervals, and corrected for the background contribution of
buffer. The sample volume was 400 mL contained in a buffer
(0.8 mM Tris, 100 mM NaCl, pH 7.4), FIXa (1 mM), 5 mM
CaCl2, with varying concentrations of C6PS [0–600 mM]).
Controls with C6PS were subtracted from each spectra. Obser-
vations were plotted as the instrumental output of ellipticity h
(mdeg).
Analysis of C6PX Binding. Binding was accessed by
recording the appropriate observable (proteolytic activity, amido-
lytic activity change, intrinsic fluorescence change, or CD
ellipticity ratio (h222/h208) as a function of soluble lipid (C6PX)
concentration over a broad range below the critical micelle
concentration (CMC) of the soluble lipid under experimental
conditions. The CMC was measured as described earlier
[10,11,19,20]. Apparent dissociation constants for binding of
FIXa to C6PS were obtained by fitting the experimental data to a
simple, single-site binding model (hyperbolic fit since
[C6PX]free[C6PX]tot), while using the approximation that
[C6PX]free<[C6PX]total [19].
Equilibrium Dialysis to Asses Stoichiometry of C6PS
Binding to FIXa. Our indirect binding measurements strongly
support the hypothesis that two types of singly occupied C6PS sites
exist on FIXa. We used equilibrium dialysis measurements to test
this hypothesis. Experiments were performed using 2.0-ml Teflon
dialysis cells (Spectrum Medical, Los Angeles, CA) with the two
cells separated by a 2 KDalton-molecular-weight-cut-off mem-
brane. Both chambers contained equal amounts of C6PS, while
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only one contained FIXa. Since inorganic phosphate determina-
tions have inherent uncertainties of about 1–2% (volumetric
measurement error), we used the highest practical concentrations
of FIXa (20, 25 mM). C6PS was added to both chambers at
sufficient concentrations (230, 240 and 250 mM) to occupy greater
than 70% of the sites on FIXa (i.e., to approach saturation). Under
these conditions, the difference in inorganic phosphorous concen-
tration between chambers (DP) will approach 10% of the lipid
concentration needed to achieve near saturation. This required
that multiple measurements be made in order to achieve the
precision required to estimate binding stoichiometries. The two
chambers were allowed to equilibrate at room temperature for
24 h while being rotated horizontally at 20 rpm. The protein
concentration gradient between the two halves of the cell causes a
difference in the total phospholipid concentration between the two
halves of the cell. The difference in phospholipid concentration
between the two chambers (DP) was measured by assaying eight
aliquots out of each chamber for total phosphate [12,14]. Total
phosphate content was similarly measured for buffer plus protein
alone as a control. A total of six independent measurements were
made in this way. It should be evident that the inherent sensitivity
of these measurements constrained the range of protein and C6PS
concentrations that could be examined, but the analysis outlined in
File S1 allowed the stoichiometries for each class of sites to be
determined by these measurements.
Results
Effect of Short Chain Soluble Lipids on FIXa Structure
We determined the intrinsic fluorescence of FIXa and the
change in CD ellipticity ratio (h222/h208) of FIXa upon binding of
C6PS in the presence of 5 mM Ca2+. These data are all presented
in Figure 1. Each data set could be described using a simple,
single-site binding isotherm (hyperbolic function) with effective
dissociation constants: Kd,eff = 1.3 mM for intrinsic fluorescence
data (Figure 1A) and Kd,eff = 5.2 mM for ellipticity ratio (Figure 1B).
The similariy of these apparent Kd’s indicates a common FIXa
structural change in response to C6PS binding to a single site or to
n1 identical and independent sites all with a common high affinity.
This conclusion is supported directly by experimental data.
Control experiments determined the critical micelle concentra-
tion (CMC) of C6PS [10] in the presence of 5 mM Ca2+ and
200 nM FIXa (inset to Figure 1A) in the presence of 0.6% PEG.
These rely on changes in pyrene’s complex florescence spectrum
that is sensitive to the polarity of its environment. Pyrene is very
hydrophobic and partitions strongly into the hydrophobic
environment in the interior of a micelle. The ratio of the intensity
of the pyrene emissions at 373 and 383 nm provides information
about the polarity of the micro-environment of the probe, and, as
such, is able to detect micelles with aggregation numbers as small
as 10, as validated by a comparison with CMC determinations by
surface tension and conductivity measurements [21,22]. The
CMC of C6PS under the conditions of our experiments was found
to be 950 mM, well above the concentration used in our studies,
thus confirming that the effects observed are due to C6PS binding
to FIXa in a monomeric form. Binding of other short chain soluble
lipids such as C6P(D)S, C6PE, C6PA, C6PG and C6PC to FIXa
was also monitored by following changes in FIXa intrinsic
fluorescence (Figure 2). These data were also adequately described
by a simple, single-site binding model (hyperbolic function when
[L]tot<[L]free), yielding Kds of 208618, 6667, 238642.7,
307628.8, and 1000645 mM for C6P(D)S, C6PE, C6PA,
C6PG and C6PC, respectively (Table 1). These results show that
only C6PS binds with high affinity to the site we have identified as
influencing FIXa structure, while C6PE apparently binds to this
site (i.e., it also influences FIXa structure) but much more weakly
than does C6PS
Effect of soluble lipids on FIXa activity. Proteolytic
activity of FIXa was measured by monitoring FIXa-catalyzed
generation of FXa from FX in the presence of increasing
concentrations of C6PS as described in Methods. Figure 3A
shows the rate of FX activation at 5 mM Ca2+ with increasing
C6PS concentration, with saturation still unachieved by almost
600 mM C6PS, well beyond the 30–50 mM seen for structural
properties in Figures 1A and 1B. The titration curve was also well
described by a single binding site hyperbolic model (Figure 3A
inset), yielding a Kd of 115610 mM for the interaction of FIXa
with C6PS, with a ,45-fold increase in proteolytic activity of
FIXa in the presence of a saturating concentration of C6PS.
Because the apparent Kd is nearly two orders of magnitude larger
than that derived from C6PS-triggered structural changes, we
conclude that proteolytic activity is regulated by a site different
from the site revealed by structural measurements in Figure 1.
With the exception of C6PE, other soluble lipids, such as C6PC,
C6PG, C6PA, and C6DPS, had no effect on the proteolytic
activity of FIXa (Table 1). C6PE increased the activity of FIXa by
a factor of 4, a tenth of the 45-fold increase produced by C6PS
(Table 1).
Figure 1. Structure Changes Induced in FIXa by C6PS as
Detected by A: Intrinsic Fluorescence and B: Circular Dichroism
Ratio h222/h208. Experiments in Frame A were performed with 0.20 mM
FIXa in 50 mM Tris, 150 mM NaCl, 5 mM CaCl2, and 0.6% PEG, pH 7.5 at
22uC while those in Frame B were performed with 1 mM FIXa in in
150 mM NaCl, 5 mM CaCl2, and 0.6% PEG, with 0.8 mM Tris buffer at
pH 7.4 and 26uC. Lines show analysis of the data according to simple
single-site hyperbolic fits to yield apparent Kd’s of 1.3 and 5.2 mM,
respectively. The h222/h208 ratio obtained without Ca
2+ is presented as
open circles. The inset to figure 1A shows the fluorescence titration of
pyrene in the presence of calcium and 0.20 mM factor IXa. There is a
sudden decrease of fluorescence near a C6PS concentration of 950 mM.
This decrease suggests that the CMC of C6PS occurs near this
concentration.
doi:10.1371/journal.pone.0100006.g001
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Figure 3B shows the amidolytic activity of FIXa (relative to
activity in the absence of C6PS) as a function of C6PS
concentration in the presence (filled circle, 5 mM) and absence
of Ca2+ (open circles). Titration of FIXa by C6PS decreased its
amidolytic activity by ,50%. A single-site (hyperbolic) fit of the
5 mM Ca2+ data gave a Kd of 130610 mM (Figure 3B inset),
which was similar to that obtained from the proteolytic data in
Figure 3A (115610 mM), strongly implying that a common site (or
set of n2 equivalent sites) regulated both amidolytic and proteolytic
activity and thus somehow the active site of FIXa. These low
affinity sites are apparently different from those that produce
global structural changes (Figure 1). Amidolytic activity was also
followed in the presence of other soluble lipids. While C6PG,
C6PC, C6PA and C6DPS did not alter the amidolytic of FIXa, a
5% decrease (as compared to the 50% decrease seen with C6PS) in
amidolytic activity was observed with C6PE (Table 1). No change
in amidolytic activity was observed in the absence of Ca2+ upon
titration with C6PS (Figure 3B, opensquares).
Effect of calcium on the structure and activity of FIXa in
the presence of C6PS
In a fashion similar to that used in Figure 1A at 5 mM Ca2+, we
monitored the change in intrinsic fluorescence of FIXa at 0, 1 and
3 mM Ca2+ to determine the optimum level of Ca2+ needed for
FIXa binding to C6PS. Our result (Figure 4A) showed that C6PS
binding increases in affinity with an increase in concentration of
Ca2+.
We also monitored CD spectra of FIXa at different C6PS
concentrations with 0 mM Ca2+ as described in Figure 1C (open
circles), and the ratio of ellipticity at 222 nm to 208 nm remained
unchanged with the addition of C6PS. Therefore, Ca2+ is required
in order to observe the global change in FIXa structure induced by
C6PS binding to its tight site on FIXa.
Measurement of proteolytic activity of FIXa with increasing
concentrations of C6PS was also carried out at varying Ca2+
concentrations (Figure 4B). The apparent Kd of interaction of
FIXa with C6PS was calculated at each Ca2+ concentration and
plotted in the inset to Figure 4. From results in the absence of Ca2+
(open circle), it is evident that Ca2+ is absolutely essential for the
FIXa proteolytic activity. The plot of apparent Kds versus Ca
2+
concentration (Figure 4A inset) clearly shows that 3 mM Ca2+ was
optimum for FX activation by FIXa in the presence of C6PS.
Michaelis-Menten Kinetics of FX activation by FIXa in the
presence of C6PS
Kinetic parameters kcat and KM of FX activation by FIXa were
determined by monitoring the initial rate of FX activation in the
presence of 400 mM C6PS at increasing concentration of FX
(Figure 5). The values of kcat and KM obtained from fitting the
curve were 0.0003860.0002/min and 3361 nM, respectively,
yielding a kcat/KM of 1.15610
4 M21 min21, similar to that
obtained in the presence of PS/PC membranes
(,1.06104 M21 min21 obtained with 25/75 sonicated PS/PC
vesicles) [17]. Thus, FIXa is comparably effective as an enzyme for
FX activation either in the presence of PS/PC membrane or
C6PS. To determine whether binding of PS to the tight binding
site in FIXa (Kd,2 mM) would cause any change in activity of
FIXa, we repeated the experiment in Figure 5 with 20 mM C6PS
so that only the tight binding site would be occupied. The kcat and
KM were determined to be 0.0002660.0001/min and
243610 nM, respectively. The overall kcat/KM
(1.160.076103 M21 min21) at 20 mM C6PS is nearly the same
as that obtained without any lipid (kcat/
KM,0.866103 M21 min21) [17]. This represents at best an
,1.3-fold increase in kcat/KM upon occupying the tight class of
sites compared to a 13.4-fold increase upon occupying the loose
class. We conclude that, while occupancy of the tight C6PS class of
sites clearly alters FIXa structure, the structural changes provoked
do not significantly alter FIXa activity.
Equilibrium Dialysis
Figures 1 and 3 provide clear evidence for two independent
classes of sites with very different site binding constants. The
curves drawn through these data are simple single site binding
isotherms, although we do not know the actual stoichiometry of
each class of sites. If the stoichiometries are other than 1, the actual
Kd’s for these sites will be larger than the apparent Kd’s obtained
Figure 2. Binding of C6P(D)S, C6PE, C6PA, C6PG & C6PC to
FIXa as Detected by Intrinsic Fluorescence. Integrated intrinsic
fluorescence of 0.20 mM FIXa in 50 mM Tris, 150 mM NaCl, 5 mM CaCl2,
and 0.6% PEG, pH 7.5 was measured as a function of C6P(D)S (Frame A),
C6PE (Frame B), C6PG(Frame C), C6PA (Frame D) and C6PC (Frame E)
concentration at 22uC to monitor binding. Single-site analysis (i.e.,
hyperbolic fits) of these curves provided apparent Kd’s of 208, 66, 238,
307 and 2000 mM, respectively.
doi:10.1371/journal.pone.0100006.g002
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from single site binding isotherms. In File S1, we derive the
thermodynamic expressions for the equilibrium distribution of
C6PS between sites assuming that each of the clearly identified
independent classes of sites have stoichiometries n1 and n2 and site
binding constants K1 and K2. These intensive or global parameters
should be the same for all experiments, while extensive parameters
such as activities, molar ellipticities, and fluorescence changes
associated with each species must be determined for each data set.
We describe in File S1 how we approached the problem of fixing
these parameters while globally fitting five data sets (intrinsic
fluorescence, ellipticity ratio, proteolytic and amidolytic activities,
and equilibrium dialysis). The equilibrium dialysis data are
formally expressed in terms of the difference in ligand (i.e.,
phosphate concentration) between the protein-containing and
protein-free chambers of the dialysis apparatus (DP), as defined by
Equation S14 in File S1. Six independently measured values for
DP are plotted in Figure 6A versus the C6PS concentrations at
which they were determined. These cluster into two groups of 3
that were obtained at two protein concentrations (20 and 25 mM;).
DP divided by the total protein concentration was less than 2 for
both equilibrium dialysis experiments. This suggests that the total
occupancy of both sites (n1+n2) should be less than 2, but does not
guarantee this, since the binding curves for occupancy of the weak
site(s) (Figure 3) do not saturate. For this reason, we allowed n1+n2
to exceed 2 and considered (n1,n2) pairs during our data fitting (see
File S1) of (0,0), (0,1), (1,0), (1,1), (0,2), (2,0) (1,2), (2,1), and (2,2).
The best description of the data was obtained with n1 = n2 = 1,
Kd1 = 1.46+1 uM, and Kd2 = 14266 mM (Table 2). The solid
black lines through each data set in Figure 6 were obtained with
the parameter values given in row 3 of Table 2, i.e., (n1,n2) = (1,1).
Figure 6F shows the species predicted by our model as a function
of added C6PS using the global parameters Kd1 = 1.4 mM,
Kd2 = 140 mM and n1 = n2 = 1.
Discussion
C6PS Binding Stoichiometry
As noted in File S1, a numerically better fit (i.e., smaller) to all
five data sets could be obtained if the constraint was removed that
n1+n2 must be whole numbers. This is shown as Fit #9 in Table 2
and illustrated by red lines in Figure 6. The lower for these
parameters derives mainly from an improved description (dashed
curves in Figure 6A) of equilibrium dialysis data (DP) collected at
25 mM FIXa (% in Figure 6A). The physically unrealistic value of
n2 required to obtain this fit (0.77, Table 2, Fit #9) also requires a
smaller Kd2 (114 mM for Fit #9 versus 140 mM for Fit #3, Table 2)
in order to correctly match the curvature of the activity titrations,
which are the only titrations whose predicted shapes depend on n2.
Despite the smaller, we must reject this set of parameters and focus
on the parameters obtained with Fit #3. Table 2 and the blue
lines in Figure 6 demonstrate that the next best whole number
(n1,n2) pair (1,2; Fit #6 in Table 2) was unacceptable both
statistically ( = 50) and visually. From this discussion, it is clear that
our data and model support only the stoichiometry (1,1), i.e., one
Table 1. Binding Affinity and Activity of FIXa in the Presence of Soluble Lipids.
Lipid
Kd, mM (determined
by monitoring
change in intrinsic
fluorescence)
Intrinsic Fluorescence
Change at Saturation
Kd, mM from
Proteolytic Activity
Increase
Proteolytic Activity
increase (in fold)
in presence of
lipids
Kd, mM from
Amidolytic
Activity Change
D% amidolytic
activity due to lipid
binding at
saturation
C6PS 1.360.2 20.204 115610 45 (3) 130610 50 (3)
C6PE 6667 20.396 175615 4(3) 250612 5 (3)
C6PC 1000645 20.170 ND None(2) ND None (2)
C6PG 307.0628.8 20.543 ND None (3) ND None (2)
C6PA 238642.7 20.509 ND None (3) ND None (3)
C6(D)PS 208618 20.088 ND None (3) ND None (2)
None-no change.
doi:10.1371/journal.pone.0100006.t001
Figure 3. Variation of (A) Proteolytic and (B) Amidolytic
Activities of FIXa Due to Addition of C6PS. A: Proteolytic
activation of 200 nM FX by 5 nM FIXa in 50 mM Tris, 150 mM NaCl,
5 mM Ca2+and 0.6%PEG, pH-7.5 at 37uC was monitored at different
concentrations of C6PS, with a fit of the data to a single site (hyperbolic)
model shown and yielding an apparent Kd of 115610 mM B: Amidolytic
activity of 300 nM FIXa in a buffer containing 50 mM Tris, 150 mM NaCl,
5 mM Ca2+and 0.6% polyethylene glycol was assayed using 1 mM
synthetic substrate Pefa-3960 and increasing concentrations of C6PS,
with a fit of the data to a single-site (hyperbolic) model, as shown,
yielding an apparent Kd of 130610 mM. The curve with open squares
represents the amidolytic activity of FIXa in the absence of Ca2+ and
with 1 mM EDTA.
doi:10.1371/journal.pone.0100006.g003
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tight and one weak site. The fact that a statistically improved fit
can be obtained with the physically unreasonable value of
n2 = 0.77 implies that our model may be missing some aspect of
the real system. This will be discussed below.
Comparison to Prothrombinase Complex
A complex of FIXa with its cofactor FVIIIa (intrinsic Xase)
activates FX by catalyzing the hydrolysis of a single peptide bond
between Arg194 and Ile195 [23,24]. This complex shows both
structural and sequence homology to the FXa-FVa complex
(prothrombinase) that catalyzes proteolysis of two peptide bonds in
prothrombin to produce the central protease of blood coagulation,
thrombin. It is well accepted that PS-containing membranes are
required for optimal functioning of both these complexes and thus
ultimately for thrombin generation. We know that C6PS regulates
both the assembly and activity of the prothrombinase complex
through interactions with C6PS-specific regulatory sites on both
FXa and FVa [10,12,14,16,25]. C6PS binds to two sites on FXa.
A tight (Kd,70–90 mM) C6PS binding site exits in the FXa EGF
(epidermal growth-factor-like) domains [12,14,16] and regulates
activity. These two domains can minimally bind C6PS but have
optimal influence on activity when these domains are linked
covalently to the Gla domain. Only acidic lipids, and mainly
C6PS, can elicit structural or functional changes when bound to
this site in the presence of Ca2+. A second, weaker (Kd,200–
600 mM) binding site is located in the catalytic domain and is only
minimally required for activity [12,14]. The appearance of the
weak site is linked to occupancy of the tight site and is suggested to
be anomalous [14] and involve serine binding (minimal ligand is
gyceryl-phosphoryl-serine) to a protein-binding site, either for FXa
to form a FXa dimer [20,25], or for FVa to form the
prothrombinase complex [26]. Both sites require Ca2+ to optimally
produce activity and structural changes.
Figure 4. Effect of Ca2+ on the intrinsic fluorescence and proteolytic activity of FIXa in the presence of C6PS. A. The response of
integrated intrinsic fluorescence to added C6PS is plotted for three different Ca2+ concentrations: 0 mM Ca2+ with 1 mM EDTA (squares), 1 mM Ca2+
(triangles), and 3 mM Ca2+ (hexagon). Hyperbolic fits of the data gave apparent Kd’s,47 mM and 3 mM for 1 and 3 mM Ca2+, respectively. B. The
proteolytic activation of FX by 25 nM FIXa at pH-7.5, was monitored at 0 mM Ca2+ (with 1 mM EDTA) – open circle, 1 mM Ca2+ - triangle, 1.5 mM Ca2+
- square, 2 mM Ca2+ - diamond, 2.5 mM Ca2+ - hexagon, 3 mM Ca2+-circle, 4 mM Ca2+ - inverted triangle, and 5 mM Ca2+ - open triangle. The inset to
4A shows a plot of apparent Kd’s obtained from hyperbolic fits of the activity data as a function of Ca
2+ concentration. The plot shows 3 mM Ca2+ is
sufficient for optimum FX activation by FIXa in the presence of C6PS.
doi:10.1371/journal.pone.0100006.g004
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While FIXa is structurally similar to FXa, we show here that its
regulation by phosphatidylserine has both similarities to and
differences from regulation of FXa by C6PS. First, we note three
similarities revealed by our results:
1] As is the case for FXa [12], FIXa is capable of activating FX in
the presence of soluble C6PS at a rate comparable to that observed
with FIXa bound to a lipid membrane. We now know that, when
bound to C6PS, the proteolytic activity of FIXa is increased 45-fold
whereas amidolytic activity is decreased to 50% (40% for FXa)
(Figure 3) (60-fold and for 40%, respectively for FXa [16]). The
second order rate constant for proteolytic activation of prothrombin
by membrane-bound FXa (9000 M21 s21) [25] is also very similar to
that for FXa bound to C6PS in solution (14,000 M21 s21) [12]. Our
data here show that the kcat and KM of FIXa-catalyzed activation of
FX in the presence of 400 mM C6PS were 0.00038/min and 33 nM
respectively (Figure 5) to give a kcat/KM of 1.1610
4 M21 min21,
similar to the rate constant found in the presence of PS/PC
membranes (1.06104 M21 min21) [17]. So, just as for FXa, it is PS
(either in solution or in membrane) not a membrane surface that
regulates FIXa activity.
2] Regulation of both FXa and FIXa activity by C6PS requires
Ca2+. Binding of C6PS to FXa is Ca2+ dependent, with optimal
binding functional/structural responses reached by roughly 3 mM
Ca2+ [16,19]. When Ca2+ binds to FIX, the protein undergoes
conformational changes [27]. The same appears to be true for
FIXa, since Ca2+ is required for C6PS-induced FIXa conforma-
tion (Figure 1B) and activity (Figure 3B) changes as is the case for
FXa [14]. Optimal binding of C6PS to FIXa occurs at around
3 mM Ca2+ (Figure 4A inset)), as is also the case for FXa. Thus,
our results show that the same Ca2+ concentration dependence for
C6PS regulation of FIXa as for C6PS regulation of FXa.
3] Lipid regulation of FIXa is specific for C6PS as is regulation
of FXa [12]. This was confirmed by measuring the proteolytic and
amidolytic activities of FIXa in the presence of C6(D)PS, C6PE,
C6PA, C6PG and C6PC (Figure 2 and Table 1). None of these
lipids had an effect on the catalytic efficiency of FIXa with the
slight exception of C6PE. FXa binds C6PE with an affinity
comparable to that with which it binds C6PS (,70–90 mM for
both lipids) [19]. Although the influence of C6PE on FXa activity
is not addressed in the literature, it produced a 4-fold increase in
Figure 5. Michaelis-Menten kinetics of FX activation by FIXa in
the presence of C6PS. The rate of activation of FX by FIXa in the
presence of 400 mM C6PS, monitored at different concentrations of FX.
Each test was performed in a buffer containing 50 mM Tris, 150 mM
NaCl, and 5 mM Ca2+. The KM and kcat for this reaction are 33 nM and
0.00038/min.
doi:10.1371/journal.pone.0100006.g005
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proteolytic activity and a 5% decrease in amidolytic activity of
FIXa, as compared to 45-fold increase and 50% decrease,
respectively, for C6PS (Table 1).
Our results here deal solely with FIXa. We have yet to examine
directly the influence of C6PS or C6PE on FVIIIIa and on its
interaction with FIXa. However, C6PS binds to FXa [12] and
FVa [13] to trigger formation of a fully active complex in solution
in the absence of any membrane [10], so it would be instructive to
explore the influence of C6PS and C6PE on FVIIIa and on its
interaction with FIXa. C6PE is reported to bind to a recombinant
human FVa2 (rHFVa2 – FVa2 is an isoform of FVa lacking a
carbohydrate chain [11]) with an apparent Kd of ,6 mM [19],
while C6PS binds to bovine FVa with an apparent Kd of 20 mM
[13]. No information was given about the stoichiometry of C6PE
binding to rHFVa2, although the stoichiometry for C6PS binding
to FVa is 4 [13], with a single site in the light chain C1 domain
regulating rHFVa2’s ability to bind to FXa [25]. If we apply a
simple equivalent, independent-site model to FVa binding to
C6PS (apparent Kd,20 mM), we would estimate that the
regulatory site in the C1 domain might have a Kd of ,5 mM, a
prediction confirmed by studies of C6PS binding to rHFVa2
mutants (Kd,3–4 mM [25]). Clearly, we need more detailed
information (stoichiometries, site locations and affinities, etc.) about
C6PS and C6PE binding to FVIIIa before we can fully understand
the regulation of the intrinsic Xase by membrane lipids such as PS
and PE and how this relates to regulation of the prothrombinase.
These studies are beyond the scope of this report but are in
progress.
Despite the similarities in PS regulation of factors Xa and IXa,
there are also three apparent differences:
1] We show clearly that the two C6PS sites in FIXa behave as if
they are independent, while the two C6PS sites on FXa appear to
be linked [20]. However, this difference is less certain when we
examine in more detail C6PS binding to the two proteins. First,
the Kd’s of the two C6PS sites on FXa differ by less than an order
of magnitude (Kd1,70–90 mM and Kd,2,200–600 mM
[12,16,20]), while those of sites on FIXa differ by two orders of
magnitude (,1.4 and 142 mM, Table 2). These are so different
that it would be difficult to detect linkage if it existed, i.e., site 1
would be essentially saturated before occupancy of site 2 became
significant. Second, the apparent linkage between sites in FXa
could be due to the fact that the apparent weak site in FXa is
located in the catalytic domain near the active site [14] and near a
residue shown to be included in the dimer interface. Since
formation of a FXa dimer is triggered by occupancy of the tight,
Figure 6. Simultaneous fit of functional and structural changes
of FIXa versus concentration of soluble C6PS. Frame A plots
results (DP as defined in File S1 versus C6PS concentration) of three
independent equilibrium dialysis experiments performed at both 20 mM
(closed circles) and 25 mM (open squares) of total FIXa. Frames B to E
reproduce data from Figures 1 and 3, but with lines obtained as
described in File S1. All data shown in Frames A to E of this figure were
fitted globally by adjusting only K1, K2, n1, and n2 (see File S1). The best
fit for n1 and n2 as natural numbers was obtained for n1, = n2 = 1 (Fit #
3) and is shown as solid black lines. Allowing n1, and n2 to be real
numbers (0.92 and 0.77, respectively) provided a fit that was statistically
only slightly improved (; red lines. The next best fit (#6) was obtained
with n1 = 1 and n2 = 2, but clearly was both numerically and visually
(blue lines) much worse. Fits with other stoichiometries were even
worse (Table 2). Frame F plots predicted FIXa species as calculated
using parameters from Fit #3- (Table 2) and the model described in File
S1 as a function of C6PS concentration.
doi:10.1371/journal.pone.0100006.g006
T
a
b
le
2
.
R
e
su
lt
s
o
f
g
lo
b
al
ly
fi
tt
in
g
fi
ve
d
at
a
se
ts
(F
IX
a
p
ro
te
o
ly
ti
c
an
d
am
id
o
ly
ti
c
ac
ti
vi
ty
,F
IX
a
in
tr
in
si
c
tr
yp
to
p
h
an
fl
u
o
re
sc
e
n
ce
In
te
n
si
ty
,a
n
d
e
lli
p
ti
ci
ty
fr
o
m
Fi
g
u
re
1
an
d
3
,a
n
d
e
q
u
ili
b
ri
u
m
d
ia
ly
si
s
d
at
a)
to
th
e
tw
o
-i
n
d
e
p
e
n
d
e
n
t-
si
te
m
o
d
e
l
w
it
h
fo
u
r
g
lo
b
al
fi
tt
in
g
p
ar
am
e
te
rs
(b
e
st
fi
t
in
b
o
ld
).
F
it
#
n
1
n
2
n
1
+n
2
K
d
,1
(m
M
)
K
d
,2
(m
M
)
P
ro
te
o
ly
ti
c
a
ct
iv
it
y
k
c
a
t,
3
(1
0
2
4
s2
1
)
R
e
la
ti
v
e
a
m
id
o
ly
ti
c
a
ct
iv
it
y
(%
)
1
1
0
1
2
5
1
.8
1
0
6
0
3
2
5
0
2
0
1
1
1
7
2
2
0
3
0
8
5
0
0
1
7
3
3
1
1
2
2
.6
1
.4
1
1
4
2
1
4
6
3
7
4
2
0
2
2
6
1
.9
1
0
5
0
3
1
0
0
5
0
2
2
1
6
1
6
7
3
1
4
5
9
2
2
2
2
6
1
2
3
5
.0
1
.4
1
3
1
7
1
9
4
1
6
7
2
1
3
8
.5
1
.4
1
4
1
7
2
2
0
5
8
2
2
4
1
0
.3
1
.4
3
6
0
2
2
6
7
0
9
0
.9
2
0
.7
7
1
.7
2
.1
1
.4
1
1
6
1
3
9
4
0
Fi
ts
1
–
8
w
e
re
o
b
ta
in
e
d
u
si
n
g
th
e
co
n
d
it
io
n
th
at
th
at
n
1
an
d
n
2
m
u
st
b
e
n
at
u
ra
l
n
u
m
b
e
rs
.
A
sl
ig
h
tl
y
lo
w
e
r
w
as
o
b
ta
in
e
d
if
w
e
re
la
xe
d
th
is
re
q
u
ir
e
m
e
n
t
(F
it
#
9
).
T
h
e
se
fi
ts
as
w
e
ll
as
th
e
n
e
xt
b
e
st
fi
t
(#
6
)
ar
e
co
m
p
ar
e
d
to
d
at
a
in
Fi
g
u
re
6
in
th
e
te
xt
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
1
0
0
0
0
6
.t
0
0
2
Regulation of FIXa by Phosphatidylserine
PLOS ONE | www.plosone.org 8 June 2014 | Volume 9 | Issue 6 | e100006
regulatory site [20,25], the apparent linkage associated with C6PS
binding to FXa could be due to structural changes associated with
dimer formation. As yet, we do not know if C6PS binding triggers
multimer formation by FIXa or whether there are functional
consequences of multimer formation.
2] The activity-regulating C6PS binding site in FXa is the tight
site (Kd,70–90 mM) [12,16], while in FIXa it is the weaker of two
sites Kd,140 mM). The tight C6PS binding site in FXa (Gla-
EGFn domains) is near the membrane surface [14]), while we do
not as yet know the location of either the tight or weak C6PS
binding sites in FIXa. As discussed above, it is conceivable that the
tight site in FIXa is near the membrane surface; if so, its
occupancy could trigger conformational changes in the catalytic
domain that allow formation of a FIXa-FVIIIa complex or a FIXa
dimer, as is the case for the prothrombinase complex. Here again,
locating the two C6PS sites in FIXa will be essential to fully
unravel how PS regulates the intrinsic Xase and whether this is
analogous to regulation of the prothrombinase. Efforts are under
way to accomplish this using modified forms or fragments of FIXa.
3] Activation of prothrombin by FXa involves cutting two
bonds, so it is difficult to make a clear comparison between the
influences of C6PS on activities of these to proteases, but an
analysis has been published of the influence of C6PS on the
Michaelis-Menten parameters for conversion of the meizothrom-
bin intermediate to thrombin [12]. Occupancy of the activity-
regulating site on FIXa enhanced kcat/KM by roughly 13-fold
(Figure 5), while occupancy of the regulatory site on FXa increased
kcat/KM for meizothrombin activation by ,200 fold [28]. Thus,
C6PS had more than an order of magnitude greater influence on
FXa proteolytic activity than it did on FIXa proteolytic activity.
Binding of C6PS to the weak site of FIXa increased kcat by only
,1.5 fold, so most of the activity enhancement by C6PS was due
to a reduction in KM by ,9-fold. Similarly, the influence of C6PS
on the kcat/KM of FXa was caused by a .26-fold decrease in KM
with an increase in kcat of only ,8 fold [28]. Thus, while the
influence of C6PS on FIXa is less than its influence on FXa, it acts
in both cases primarily by decreasing KM.
In summary, although there are apparent differences between
the regulation of FXa and FIXa by lipids, it still may be that
further studies will reveal the expected analogy. Given the key role
of the intrinsic Xase in amplifying the initial response to injury
mounted by the extrinsic Xase [29], understanding this lipid
regulation is of great significance physiologically. Our results
provide the groundwork needed to extend our knowledge of this
regulation, but additional studies are needed to establish the
locations of both the tight and weak sites on FIXa, determine
whether C6PS triggers formation of a FIXa multimer as it does a
FXa dimer, and finally to determine whether occupancy of the
tight site is linked to binding of another protein such as a molecule
of FIXa or the cofactor VIIIa.
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